Avita Medical says a new patent award for its regenerative skin related technology has strengthened its commercial grip in the world's third largest healthcare market behind the US and Europe, Japan.

Drug development company, Phytopharm, has begun talks with potential buyers for the company after it confirmed the results of its Phase II clinical trial of Cogane in Parkinson's disease, which showed that the drug had demonstrated no clinically meaningful efficacy.

Cambridge Cognition, the company promising to cut down the diagnosis of dementia from 18 months to just three, is to undertake a multimillion pound stock market listing.

It is said that Cambridge and UK companies sell out too early, but today, a deal that took place seven years ago and saw Cambridge's most successful biotech firm acquired for £702 million has led to a new £330 million commitment to Cambridge which will become the global HQ for one of the world's largest pharmaceutical companies.

Groundbreaking work to map the genomes of tapeworms has revealed existing drugs that could be used against them in an effort to halt at least two of the world's most high profile neglected tropical diseases.

Horizon Discovery has announced the creation of two new centres of excellence (CoE) in Cambridge based on its gene editing technology including one at the Gurdon Institute, named after the Nobel Prize winning scientist, Professor Sir John Gurdon, whose early work has paved the way for cutting edge animal cloning and stem cell work.

Dutch technology heavyweight, Royal DSM, has taken a minority stake in Cambridge biotech firm, Arecor, whose protein stabilisation technology has far reaching potential in the development, manufacture and delivery of new biological medicines.

Lab21, a specialist in personalised medicine and clinical diagnostics, has entered into an agreement with IntegraGen to develop a microRNA assay for colorectal cancer with the potential to improve treatments.

Sphere Fluidics is looking to expand into new offices to accommodate a growing workforce who can accelerate commercialisation of its single cell analysis technology following a £1.6 million Series A funding round.

Cancer focused drug discovery firm, Domainex, is looking for a second close on a £1.5 million fundraising round to allow it to select a drug candidate to license out to a pharmaceutical partner.

Researchers from Cambridge University have discovered a 'quadruple helix' structure in human DNA which they believe could provide a new point of attack in the battle against cancer and halt what they call the runaway cell proliferation at the root of cancer.

Ithaka Life Sciences has teamed up with researchers from De Montfort University to commercialise a new technology they say could lower the costs and time spent on drug discovery work by improving early toxicity testing on cytochrome P450 the most important group of enzymes used by the human body to metabolise drugs.

Lab21 has divested its US operations through a locally based management buy-out for an undisclosed fee.

A Cambridge medical devices startup that uses 3D technology to analyse respiratory ailments with greater accuracy and less 'invasion' than many current techniques plans to raise up to £3 million this year to help take its technology stateside.

GlaxoSmithKline’s venture capital division, SR One, and Oxbridge Biotech Roundtable (OBR) are to launch a £100k cash prize competition to medical technology entrepreneurs fresh out of university.

Cancer drug developer, Sareum, says it is now unlikely to close its first internal licensing deal before the end of the year, sending its share price down by almost 20 per cent.

Bicycle Therapeutics, the drug discovery firm set up by the man behind Cambridge’s largest ever biotech sale, CAT, is to start work on its first drug candidates after it raised £3.75 million in VC investment, its first funding round in over two and a half years.

Cambridge scientists have engineered a possible breakthrough in the treatment of one of the most dangerous hospital 'supoerbugs', Clostridium difficile.

Novartis has filed the Vectura drug for chronic obstructive pulmonary disease (COPD), QVA149, with the European Medicines Agency (EMA), triggering a $5 million milestone payment to the Chippenham and Cambridge biotech firm.

Astex Pharmaceuticals’ lung cancer treatment – AT13387 – has entered Phase 2 clinical trials to test the drug’s safety and efficacy as a stand alone treatment or in combination with the established crizotinib drug.